Patents by Inventor Gene Kinney
Gene Kinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965005Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: GrantFiled: June 2, 2023Date of Patent: April 23, 2024Assignee: OTHAIR PROTHENA LIMITEDInventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Patent number: 11952406Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: GrantFiled: June 2, 2023Date of Patent: April 9, 2024Assignee: OTHAIR PROTHENA LIMITEDInventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Patent number: 11945849Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: GrantFiled: June 2, 2023Date of Patent: April 2, 2024Assignee: OTHAIR PROTHENA LIMITEDInventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Publication number: 20230391859Abstract: Provided herein are methods and compositions for detecting, reducing, and inhibiting misfolded transthyretin protein.Type: ApplicationFiled: October 28, 2021Publication date: December 7, 2023Inventors: Frédérique Bard, Gene Kinney, Wagner Zago, Radhika Tripuraneni
-
Publication number: 20230364210Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer’s disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A?, blocking the uptake by neurons, and clearing amyloid in a subject having or at risk of developing Alzheimer’s disease or other diseases containing amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an. amyloid-beta (A?) peptide.Type: ApplicationFiled: May 19, 2021Publication date: November 16, 2023Inventors: Robin Barbour, Gene Kinney, Wagner Zago
-
Publication number: 20230355729Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing alpha-synuclein and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and an alpha-synuclein peptide.Type: ApplicationFiled: August 6, 2021Publication date: November 9, 2023Inventors: Robin Barbour, Gene Kinney, Wagner Zago
-
Publication number: 20230355756Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of neurodegenerative diseases, such as Parkinson’s disease, dementia with Lewy bodies (DLB), Alzheimer’s disease or other synucleinopathies, with alpha-synuclein deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of alpha-synuclein, blocking the uptake by neurons and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing a neurodegenerative disease containing alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising alpha-synuclein peptide.Type: ApplicationFiled: August 6, 2021Publication date: November 9, 2023Inventors: Robin Barbour, Gene Kinney, Wagner Zago
-
Publication number: 20230331831Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.Type: ApplicationFiled: May 8, 2023Publication date: October 19, 2023Applicant: Prothena Biosciences LimitedInventors: Gene Kinney, Wagner Marcelo Zago, Carol Karp, Radhika Tripuraneni
-
Publication number: 20230322876Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: ApplicationFiled: June 2, 2023Publication date: October 12, 2023Inventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Publication number: 20230312662Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: ApplicationFiled: June 2, 2023Publication date: October 5, 2023Inventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Publication number: 20230302127Abstract: The disclosure provides peptides, peptide compositions, immunotherapy compositions, pharmaceutical compositions and nucleic acids comprising one or more tau peptides. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases characterized at least in part by aberrant tau pathology (e.g., aggregation in neurofibrillary tangles) in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of tau, blocking the uptake by neurons, clearing tau, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau accumulations. The methods include administering to such patients the compositions comprising one or more tau peptides.Type: ApplicationFiled: May 19, 2021Publication date: September 28, 2023Inventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Publication number: 20230295254Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: ApplicationFiled: June 2, 2023Publication date: September 21, 2023Inventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Patent number: 11692024Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.Type: GrantFiled: March 5, 2020Date of Patent: July 4, 2023Assignee: Prothena Biosciences LimitedInventors: Gene Kinney, Carol Karp, Wagner Marcelo Zago, Radhika Tripuraneni
-
Publication number: 20230183304Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a fau. peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or oilier diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tan, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: ApplicationFiled: May 19, 2021Publication date: June 15, 2023Inventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan Nijjar
-
Publication number: 20200308260Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.Type: ApplicationFiled: March 5, 2020Publication date: October 1, 2020Inventors: Gene KINNEY, Carol KARP, Wagner Marcelo ZAGO, Radhika TRIPURANENI
-
Patent number: 8889138Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 11, 2010Date of Patent: November 18, 2014Assignees: Merck Sharp & Dohme Corp., Northwestern UniversityInventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Patent number: 8420093Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: January 30, 2012Date of Patent: April 16, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Gene Kinney, William R. Strohl, Zhiqiang An
-
Patent number: 8383113Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: February 8, 2012Date of Patent: February 26, 2013Assignees: Northwestern University, Merck Sharp & Dohme Corp.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Publication number: 20120171224Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: February 8, 2012Publication date: July 5, 2012Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Publication number: 20120164158Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: January 30, 2012Publication date: June 28, 2012Applicant: MERCK SHARP & DOHME CORP.Inventors: GENE KINNEY, WILLIAM R. STROHL, ZHIQIANG AN